Form 4: Bioadaptives Director Mark Frissora Receives Significant Convertible Preferred Stock as Compensation

Bioadaptives, Inc. Director Mark P. Frissora was issued 847 shares of Series D Convertible Preferred Stock as compensation for board services, convertible into 84,700 shares of common stock.

Summary

• Mark P. Frissora, a Director and 10% Owner of Bioadaptives, Inc. (BDPT), received 847 shares of Series D Convertible Preferred Stock.
• The issuance was compensation for board services, as per a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, implying a potential conversion of 84,700 common shares from this transaction.
• Conversion is subject to a 10% beneficial ownership limitation.
• Conversion is generally restricted for six months from the issuance date, unless in the case of liquidation, where conversion occurs immediately.
• Each Series D share carries 100 votes on Issuer matters, irrespective of the beneficial ownership limitation.
• The right to convert Series D Preferred Stock does not expire.
• Following this transaction, Mark P. Frissora beneficially owns 47,194 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The issuance of equity compensation aligns director interests, which is generally positive for governance. However, potential future dilution and concentrated voting power could be seen as minor negatives depending on perspective.

Positives

• Issuance of equity compensation aligns the interests of Director Mark P. Frissora with those of shareholders.
• The Series D Convertible Preferred Stock provides significant voting power (100 votes per share) to a key director, potentially indicating strong governance influence.

Negatives

• The conversion of Series D Preferred Stock into common stock could lead to future dilution for existing common shareholders.
• The significant voting power associated with Series D Preferred Stock (100 votes per share) concentrates control, potentially impacting minority shareholder influence.
• The 10% beneficial ownership limitation on conversion might restrict immediate liquidity or full conversion for the holder.

Risks

• Potential future dilution of common stock due to the conversion of Series D Convertible Preferred Stock.
• Concentration of voting power with Series D Preferred Stock holders, potentially impacting corporate governance dynamics.
• Restrictions on conversion (six-month lock-up period and 10% beneficial ownership limitation) could affect the liquidity and flexibility of the preferred stock.

Future Outlook

The Series D Convertible Preferred Stock has no expiration date for conversion rights, indicating a long-term equity interest for the reporting person.

Industry Context

This Form 4 filing reflects a standard practice of using equity compensation to align the interests of directors with the company's long-term performance. The issuance of preferred stock with significant voting rights is a common mechanism for retaining key personnel and granting them substantial influence in corporate governance, particularly in smaller or developing companies.

Comparison to Industry Standards

• The use of convertible preferred stock as director compensation is a common practice across various industries, particularly in growth-oriented companies or those seeking to conserve cash.
• The 100:1 conversion ratio and 100 votes per preferred share are specific to Bioadaptives' capital structure and governance design, making direct comparisons to other companies without detailed knowledge of their specific preferred stock terms difficult.
• The beneficial ownership limitation (10%) is a common feature to prevent immediate excessive control or dilution upon conversion.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• The issuance of Series D Convertible Preferred Stock to Director Mark P. Frissora constitutes a related party transaction, as it involves compensation from the Issuer to a member of its board and a 10% owner.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon conversion of Series D Preferred Stock. The significant voting power of Series D shares could impact the influence of common shareholders in corporate decisions.
• Management: The compensation structure incentivizes the director to contribute to the company's long-term success.

Next Steps

• The Series D Convertible Preferred Stock will become convertible into common stock six months after the issuance date, unless a liquidation event occurs sooner.

Key Dates

Recommendation

Keywords

SEC Form 4, Insider Trading, Director Compensation, Convertible Preferred Stock, Equity Compensation, BIOADAPTIVES INC, BDPT, Mark P Frissora, Corporate Governance, Share Dilution, Voting Rights